Gilead Sciences, Inc. SEC filings GILD

Gilead Sciences, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Apr 2, 2018. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Gilead Sciences, Inc. SEC filings
Form Description Filed Period
S-3ASR Automatic shelf registration Aug 6, 2026 —
424B5 Prospectus supplement May 18, 2026 —
FWP Free writing prospectus May 14, 2026 —
424B5 Prospectus supplement May 14, 2026 —
S-8 Employee stock plan registration May 7, 2026 —
424B5 Prospectus supplement Nov 15, 2024 —
FWP Free writing prospectus Nov 13, 2024 —
424B5 Prospectus supplement Nov 13, 2024 —
424B5 Prospectus supplement Sep 11, 2023 —
FWP Free writing prospectus Sep 7, 2023 —
424B5 Prospectus supplement Sep 7, 2023 —
S-8 Employee stock plan registration Aug 7, 2023 —
S-3ASR Automatic shelf registration Aug 4, 2023 —
S-8 Employee stock plan registration May 5, 2022 —
S-8 Employee stock plan registration Nov 4, 2020 —
424B5 Prospectus supplement Sep 25, 2020 —
FWP Free writing prospectus Sep 24, 2020 —
424B5 Prospectus supplement Sep 23, 2020 —
S-3ASR Automatic shelf registration Aug 7, 2020 —
S-8 Employee stock plan registration May 20, 2020 —

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
GILD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Foster City, CA
SEC filer status
Large accelerated filer
SEC CIK
882095
Former names
GILEAD SCIENCES INC (until Feb 17, 2022)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.